RIPK1 promotes inflammation and β-amyloid accumulation in Alzheimer's disease.

02 May 2018

Alzheimer’s disease (AD), the leading cause of dementia, is a major cause of death and a significant economic burden. In 2016, ∼700,000 Americans aged 65 and over died of AD, and the total health and social care payments for AD in the United States alone exceeded $230 billion (1). Currently, there are no validated disease-modifying therapies that slow the progression of human AD.